BIOCYTOGEN
5.1.2023 22:02:38 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially launched its fully human heavy chain antibody platform, RenNano®. RenNano® is the third member of the RenMice™ family, joining RenMab™ and RenLite®. Together, Biocytogen’s three RenMice™ platforms allow for the streamlined discovery and development of fully human monoclonal antibodies, bispecific/multispecific antibodies and single-domain antibodies (sdAbs, or nanobodies) (Figure 1).
While humans and mice generate antibodies that require heavy and light chain pairing to be functional, camels and sharks generate heavy-chain-only antibodies (HCAb), meaning their variable domains (VHH or sdAb) can function without pairing with the light chain. Owing to their nanometer-level size and small molecular weight, sdAbs have superior permeability, and thus can cross the blood-brain barrier and infiltrate solid tumor tissues. In addition, the longer CDR3 region enables sdAbs to detect the otherwise hidden epitopes of GPCRs and other challenging targets. Since sdAbs have a simple structure, they are ideal building blocks for assembling bispecific/multispecific antibodies and CAR cell therapies.
While nanobodies have its unique advantages, animals that naturally produce HCAbs, such as camels, are difficult to be widely used for the preparation of monoclonal antibodies because they are large, having a long breeding cycle and generate few offspring. Meanwhile, humanization is required to develop camelid antibody sequences into drugs, which further increases the complexity and time of drug development.
To overcome these challenges, Biocytogen engineered the RenNano® mouse by modifying the constant region of the fully human RenMab™ model to allow for HCAb production. Compared with other existing HCAb platforms, the in situ replacement of the mouse genes with the complete human heavy chain variable genes makes the RenNano® mouse one of the most comprehensive fully human antibody platforms in the world. SdAb sequences generated from RenNano® mice have the highest possible diversity, and do not require antibody humanization, which saves time and cost, and reduces risk of failure during later stages of drug development. Additionally, compared with camelids or other natural HCAb-producing species, mice are easier to breed and immunize. Immunization of RenNano® mice can generate HCAbs with diverse CDR3 sequences that recognize a variety of epitopes. These HCAbs can recognize antigens with nM-level affinity independent of light chains. Moreover, antibodies derived from RenNano® mice are capable of exerting biological functions both in vitro and in vivo. They are highly hydrophilic and have favorable developability characteristics.
The successful development of the RenNano® platform expands Biocytogen’s capabilities for antibody discovery and broadens the applications of our antibody library. We welcome global partners to realize the full potential of our RenMice™ platforms and derive antibodies to generate novel therapeutics.
About RenMice
RenMice™, i.e., RenMab™, RenLite® and RenNano® mice, which have proprietary intellectual property rights, were developed by Biocytogen over the course of 5 years using size-unlimited, precise chromosome engineering technology (SUPCE). RenMice™ is one of the top 3 fully human antibody mice made by in situ replacement technology globally. All RenMice™ members contain full human heavy chain VDJ loci replaced in situ. Regarding antibody κ light chains, RenMab™ mouse contains full human VJ loci replaced in situ and RenLite® mouse contains a single human VJ locus replaced in situ. RenNano® mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice™ can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. Using RenMice™, Biocytogen has built 6 fully human antibody discovery platforms, covering various types of targets and modalities such as monoclonal antibody (RenMab™), bispecific antibody and bispecific ADC (RenLite®), nanobody (RenNano®), TCR-mimic antibody for intracellular targets (HLA/RenMice, humanized RenMice™), and antibody platform against GPCR and other challenging targets (RenMice™ knockouts).
RenMice™ has been recognized by top biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen:
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal antibody, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005963/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Announces Results of the Annual General Meeting2.4.2026 16:49:00 CEST | Press release
SES (the “Company”) held the Annual General Meeting (“AGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions, including the Company’s 2025 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total dividend amount comprises the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share), which has already been paid to shareholders on October 16, 2025. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on April 16, 2026. “I would like to sincerely thank our shareholders for their active engagement, visionary support and continued confidence in SES’ strategy,” said Adel Al-Saleh, CEO of SES. “The outcomes of today’s AGM underscore our shared commitment to a bold multi-orbit approach, with Medium Earth Orbit as the strategic backbone of a dynamically evolving global interco
Andersen Consulting styrker sine kompetencer med tilføjelsen af Lukkap2.4.2026 16:31:00 CEST | Pressemeddelelse
Andersen Consulting tilføjer samarbejdspartneren Lukkap, et konsulenthus med fokus på oplevelsesdrevne kompetencer, der er tilpasset kundernes skiftende behov inden for transformation af medarbejdere, kunder og det digitale område. Lukkap, der blev stiftet i 2009 og har hovedsæde i Spanien, leverer integrerede løsninger, der hjælper organisationer med at transformere, hvordan de betjener kunder, engagerer medarbejdere og frigør værdi gennem adfærdsindsigt og dataanalyse. Virksomhedens tværfaglige tilgang spænder over nytænkning af kunderejsen, effektive programmer for medarbejderoplevelser, talent- og ledelsesudvikling, prædiktiv analyse samt omfattende outplacement- og transitionsydelser. Lukkap arbejder på tværs af sektorer — herunder sundhedsvæsen, medicinalindustri, forbrugsgoder, detailhandel, finans og bankvæsen — for at opbygge menneskecentrerede strategier, der skaber målbare forretningsresultater. "Ved at kombinere vores erfaringsdrevne metode med Andersen Consultings globale
Forrester: Three Years Into GenAI, Enterprises Are Still Chasing Its True Transformative Value2.4.2026 16:00:00 CEST | Press release
Low AI fluency, uneven adoption, and marginal productivity gains are limiting enterprise-scale impact According to Forrester’s (Nasdaq: FORR) latest report, Accelerate Your AI Voyage, most enterprises are struggling to turn growing AI adoption and investment into measurable business impact. One of the key factors holding businesses back is low artificial intelligence quotient (AIQ) — Forrester’s measure of AI aptitude — with many employees lacking a clear understanding of how to use AI. Other barriers include an overemphasis on productivity-focused use cases, difficulty measuring impact, and siloed adoption within individual functions. While these challenges can leave firms frozen in doubt or indecision, the wait-and-see approach to AI adoption is no longer viable. To unlock AI’s full potential, organizations need to focus on four key areas: Define the business outcomes and success metrics for what they want AI to achieve; identify specific use cases for AI deployment aligned to those
The LYCRA Company Announces Strategic Partnership on Renewable LYCRA® Fiber2.4.2026 15:00:00 CEST | Press release
Agreement with Texhong Advances Sustainable Fiber Applications The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the apparel and personal care industries, today announced the signing of a strategic partnership agreement with Texhong International Group Limited (“Texhong”), one of the world’s largest suppliers of core-spun cotton textiles. Under the agreement, Texhong will exclusively partner with The LYCRA Company to bring Renewable LYCRA® fiber made with 30 percent plant-based content* to China’s core-spun yarn sector. This collaboration aims to accelerate the adoption of bio-derived spandex across the global apparel and textile industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402505834/en/ The LYCRA Company announced a strategic partnership with Texhong International Group for renewable LYCRA® fiber. Pictured at the signing ceremony held in Shanghai (left to right): Jason Wang,
Brightfin Unifies Brand Following Proven Optics Merger, Delivering a New Standard for Technology Cost Optimization2.4.2026 15:00:00 CEST | Press release
New identity reflects expanded vision to help CIOs “See Clearly. Spend Better.” Brightfin today announced that, following its merger with Proven Optics, the combined company will operate under a single brand: Brightfin. The unified company brings together deep expertise in Technology Expense Management (TEM) and IT Financial Management (ITFM) to help organizations better understand, manage, and reduce total technology spend. Technology spending will exceed $6 Trillion this year, and for most organizations, it remains one of the least understood. CIOs can tell you what they’re spending. Far fewer can tell you whether it’s working. “Over the past several months, we’ve brought these two businesses together around a shared purpose: help enterprise businesses better understand and optimize their technology spend,” said Joel Martins, CEO of Brightfin. “What we are seeing now is a shift. Visibility alone isn’t enough. Teams need to be able to act, tied to real financial outcomes. See Clearly.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom